<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01267604</url>
  </required_header>
  <id_info>
    <org_study_id>rFSH-INOPLUS</org_study_id>
    <nct_id>NCT01267604</nct_id>
  </id_info>
  <brief_title>Ovarian Stimulation: Inositol and Melatonin</brief_title>
  <official_title>Improving Oocyte Retrieval Using a Combined Therapy of Recombinant Follicle Stimulating Hormone (rFSH) and Inositol and Melatonin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGUNCO Obstetrics and Gynecology Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Modena and Reggio Emilia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research Center for Reproductive Medicine Villa Mafalda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AGUNCO Obstetrics and Gynecology Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An efficient protocol of ovarian stimulation is a key part of assisted reproductive
      technology. In order to obtain the highest oocyte retrieval with no adverse effects, numerous
      studies have evaluated the efficiency of the clinical approaches currently available.

      Recent studies have shown that two natural compounds, such as inositol and melatonin, play an
      important role in oocyte maturation and quality. Therefore, the present study aims at
      investigating whether inositol and melatonin are able to improve the number of oocytes
      obtained after ovarian stimulation with Recombinant Follicle Stimulating Hormone (rFSH).

      To this purpose, a randomized double-blind trial will be established where 150 healthy women
      in reproductive age undergoing to assistant reproductive technology (ART) because of male
      infertility will be divided in two groups. Group A will be treated with 225IU rFSH alone,
      group B will be treated with 225IU rFSH, 4g inositol and 3mg melatonin.

      As primary outcome of the study, oocyte quality, total number of oocytes retrieved, clinical
      pregnancy rate and live birth rate will be evaluated in group A vs. group B.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total oocyte number</measure>
    <time_frame>2 weeks after pharmacological treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinical pregnancies</measure>
    <time_frame>6 weeks after embryo transfer</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>10 months after embryo transfer</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Recombinant FSH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>225IU rFSH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recombinant FSH Inositol Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>225IU rFSH, 4g Inositol and 3mg Melatonin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant FSH (rFSH)</intervention_name>
    <description>225IU</description>
    <arm_group_label>Recombinant FSH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>rFSH + Inositol + Melatonin</intervention_name>
    <description>225IU rFSH, 4g Inositol, 3mg Melatonin</description>
    <arm_group_label>Recombinant FSH Inositol Melatonin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female age 18-39 years

          -  BMI 18-30 kg/m2,

          -  Fewer than 3 prior oocyte retrievals,

          -  No fertility Problems
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vittorio Unfer, MD</last_name>
    <role>Study Director</role>
    <affiliation>AGUNCO Obstetrics and Gynecology Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gianfranco Carlomagno, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AGUNCO Obstetrics and Gynecology Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>La Sala Giovanni Battista, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Modena and Reggio Emilia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franco Lisi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Center for Reproductive Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vittorio Unfer, MD</last_name>
    <phone>+39 0640500835</phone>
    <email>vunfer@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gianfranco Carlomagno, PhD</last_name>
    <email>gianfranco.carlomagno@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Modena and Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Battista La Sala, MD</last_name>
      <phone>+39 0522 296464</phone>
      <email>giovanni.lasala@asmn.re.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Battista La Sala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Center for Reproductive Medicine Villa Mafalda</name>
      <address>
        <city>Roma</city>
        <zip>00199</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Lisi, MD</last_name>
      <phone>+39 06 86094776</phone>
      <email>flisi@tin.it</email>
    </contact>
    <investigator>
      <last_name>Franco Lisi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Rizzo P, Raffone E, Benedetto V. Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. Eur Rev Med Pharmacol Sci. 2010 Jun;14(6):555-61.</citation>
    <PMID>20712264</PMID>
  </reference>
  <reference>
    <citation>Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol. 2009 Dec;147(2):120-3. doi: 10.1016/j.ejogrb.2009.09.008. Epub 2009 Oct 2. Review.</citation>
    <PMID>19800728</PMID>
  </reference>
  <reference>
    <citation>Tamura H, Nakamura Y, Korkmaz A, Manchester LC, Tan DX, Sugino N, Reiter RJ. Melatonin and the ovary: physiological and pathophysiological implications. Fertil Steril. 2009 Jul;92(1):328-43. doi: 10.1016/j.fertnstert.2008.05.016. Epub 2008 Sep 18. Review.</citation>
    <PMID>18804205</PMID>
  </reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2010</study_first_posted>
  <last_update_submitted>December 27, 2010</last_update_submitted>
  <last_update_submitted_qc>December 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>AGUNCO Obstetrics &amp; Gynecology Center</name_title>
    <organization>AGUNCO Obstetrics &amp; Gynecology Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Inositol</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

